- Home
- PEN vs MRNA Comparison
PEN vs MRNA Comparison
Compare PEN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- MRNA
- Stock Information
- Founded
- PEN 2004
- MRNA 2010
- Country
- PEN United States
- MRNA United States
- Employees
- PEN N/A
- MRNA N/A
- Industry
- PEN Medical/Dental Instruments
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEN Health Care
- MRNA Health Care
- Exchange
- PEN Nasdaq
- MRNA Nasdaq
- Market Cap
- PEN 9.7B
- MRNA 9.8B
- IPO Year
- PEN 2015
- MRNA 2018
- Fundamental
- Price
- PEN $231.31
- MRNA $24.98
- Analyst Decision
- PEN Strong Buy
- MRNA Hold
- Analyst Count
- PEN 16
- MRNA 15
- Target Price
- PEN $307.50
- MRNA $37.15
- AVG Volume (30 Days)
- PEN 370.3K
- MRNA 11.1M
- Earning Date
- PEN 11-05-2025
- MRNA 11-06-2025
- Dividend Yield
- PEN N/A
- MRNA N/A
- EPS Growth
- PEN 916.05
- MRNA N/A
- EPS
- PEN 3.74
- MRNA N/A
- Revenue
- PEN $1,280,152,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PEN $15.52
- MRNA N/A
- Revenue Next Year
- PEN $14.20
- MRNA $11.12
- P/E Ratio
- PEN $60.50
- MRNA N/A
- Revenue Growth
- PEN 12.92
- MRNA N/A
- 52 Week Low
- PEN $221.26
- MRNA $23.15
- 52 Week High
- PEN $310.00
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- PEN 34.48
- MRNA 44.14
- Support Level
- PEN $221.26
- MRNA $24.25
- Resistance Level
- PEN $260.00
- MRNA $29.20
- Average True Range (ATR)
- PEN 7.60
- MRNA 1.46
- MACD
- PEN -2.31
- MRNA -0.20
- Stochastic Oscillator
- PEN 25.94
- MRNA 14.65
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.